

# David Goldstein

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/546740/david-goldstein-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264  
papers

12,988  
citations

50  
h-index

110  
g-index

285  
ext. papers

15,384  
ext. citations

5.2  
avg, IF

5.97  
L-index

#	Paper	IF	Citations
264	INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS366-TPS366	2.2	
263	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.. <i>Targeted Oncology</i> , <b>2022</b> , 17, 95	5	1
262	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy.. <i>Supportive Care in Cancer</i> , <b>2022</b> , 1	3.9	0
261	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 1-13	3.5	
260	Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , <b>2021</b> , 11, 22884	4.9	2
259	Psychological predictors of advanced cancer patients' preferences for return of results from comprehensive tumor genomic profiling. <i>American Journal of Medical Genetics, Part A</i> , <b>2021</b> ,	2.5	1
258	The effect of exercise intensity on exercise-induced hypoalgesia in cancer survivors: A randomized crossover trial. <i>Physiological Reports</i> , <b>2021</b> , 9, e15047	2.6	
257	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS). <i>Annals of</i>	10.3	5
256	Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. <i>Supportive Care in Cancer</i> , <b>2021</b> , 29, 6379-6387	3.9	2
255	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. <i>Cancer Research</i> , <b>2021</b> , 81, 3461-3479	10.1	15
254	Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
253	Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients. <i>Patient Education and Counseling</i> , <b>2021</b> , 105, 452-452	3.1	2
252	Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4172-TPS4172	2.2	1
251	Longitudinal patterns in fear of cancer progression in patients with rare, advanced cancers undergoing comprehensive tumour genomic profiling. <i>Psycho-Oncology</i> , <b>2021</b> , 30, 1920-1929	3.9	
250	Value of whole-genome sequencing to Australian cancer patients and their first-degree relatives participating in a genomic sequencing study. <i>Journal of Genetic Counseling</i> , <b>2021</b> ,	2.5	1
249	Corneal nerve changes following treatment with neurotoxic anticancer drugs. <i>Ocular Surface</i> , <b>2021</b> , 21, 221-237	6.5	4
248	Family communication about genomic sequencing: A qualitative study with cancer patients and relatives. <i>Patient Education and Counseling</i> , <b>2021</b> , 104, 944-952	3.1	2

247	Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. <i>Pancreatology</i> , <b>2021</b> , 21, 103-114	3.8	3
246	Ex vivo culture of intact human patient derived pancreatic tumour tissue. <i>Scientific Reports</i> , <b>2021</b> , 11, 1944	4.9	12
245	Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. <i>Brain, Behavior, &amp; Immunity - Health</i> , <b>2021</b> , 10, 100189	5.1	1
244	Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. <i>Journal of Cancer Survivorship</i> , <b>2021</b> , 1	5.1	7
243	Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2036695	10.4	11
242	Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 821-828	7.3	10
241	Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 993-1002	4	2
240	AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. <i>BMC Cancer</i> , <b>2021</b> , 21, 936	4.8	1
239	Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Gait and Posture</i> , <b>2021</b> , 89, 178-185	2.6	1
238	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 348-348	2.2	
237	Acute changes in nerve excitability following oxaliplatin treatment in mice. <i>Journal of Neurophysiology</i> , <b>2020</b> , 124, 232-244	3.2	6
236	Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1486-1495	8.7	18
235	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , <b>2020</b> , 155, e200397	5.4	14
234	Impact of migrancy on cancer clinical trial participation: Factors associated with approach and consent in Australian-born versus migrant groups. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, 115-122	1.9	2
233	Self-reported health, lifestyle and social circumstances of Australian adult cancer survivors: A propensity score weighted cross-sectional study. <i>Cancer Epidemiology</i> , <b>2020</b> , 67, 101773	2.8	1
232	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 2506-2515	3.1	6
231	The impact of anticancer drugs on the ocular surface. <i>Ocular Surface</i> , <b>2020</b> , 18, 403-417	6.5	8
230	Phase III AFACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4515-4515	2.2	5

229	Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4618-4618	2.2	1
228	The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas. <i>Oncotarget</i> , <b>2020</b> , 11, 46-61	3.3	1
227	Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1541-1541	2.2	
226	Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e24080-e24080	2.2	
225	Barriers and enablers to the implementation of protocol-based imaging in pancreatic cancer: A qualitative study using the theoretical domains framework. <i>PLoS ONE</i> , <b>2020</b> , 15, e0243312	3.7	1
224	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1109-1117	13.4	9
223	The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta Oncologica</i> , <b>2020</b> , 59, 20-27	3.2	3
222	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. <i>Biomaterials</i> , <b>2020</b> , 240, 119742	15.6	29
221	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , <b>2020</b> , 10, e136-e146	2.8	21
220	Advanced cancer patient preferences for receiving molecular profiling results. <i>Psycho-Oncology</i> , <b>2020</b> , 29, 1533-1539	3.9	1
219	Targeting HGF/c-MET Axis in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
218	Determining the CA19-9 concentration that best predicts the presence of CT-occult unresectable features in patients with pancreatic cancer: A population-based analysis. <i>Pancreatology</i> , <b>2020</b> , 20, 1458-1464	3.8	1
217	Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1466	8.7	1
216	Assessment of the Value of Tumor Variation Profiling Perceived by Patients With Cancer. <i>JAMA Network Open</i> , <b>2020</b> , 3, e204721	10.4	4
215	Oxaliplatin-induced haematological toxicity and splenomegaly in mice. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238164	3.7	4
214	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. <i>Journal of Pain</i> , <b>2020</b> , 21, 44-58	5.2	12
213	Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. <i>Journal of Cancer Survivorship</i> , <b>2019</b> , 13, 495-502	5.1	10
212	Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 4771-4777	3.9	19

211	Challenges and perceived unmet needs of Chinese migrants affected by cancer: Focus group findings. <i>Journal of Psychosocial Oncology</i> , <b>2019</b> , 37, 383-397	2.8	6
210	Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , <b>2019</b> , 58, 1023-1032	4.8	15
209	Patient perspectives on molecular tumor profiling: "Why wouldn't you?". <i>BMC Cancer</i> , <b>2019</b> , 19, 753	4.8	12
208	Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1472-1478	10.3	71
207	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4000-4000	2.2	78
206	NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4156-TPS4156	2.2	2
205	Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2019</b> , 17, 949-955	7.3	12
204	Medical oncologists' experience with returning molecular tumor profiling to patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 10521-10521	2.2	0
203	CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine. <i>Future Oncology</i> , <b>2019</b> , 15, 1295-1302	3.6	17
202	Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 3849-3857	3.9	38
201	Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. <i>Oncologist</i> , <b>2019</b> , 24, e1102-e1107	5.7	5
200	Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. <i>Pancreas</i> , <b>2019</b> , 48, 1274-1284	2.6	2
199	Dorsal root ganglion explants derived from chemotherapy-treated mice have reduced neurite outgrowth in culture. <i>Neuroscience Letters</i> , <b>2019</b> , 694, 14-19	3.3	12
198	Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. <i>Hpb</i> , <b>2019</b> , 21, 444-455	3.8	13
197	Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 119, 489-496	2.8	6
196	Evaluation of an online communication skills training programme for oncology nurses working with patients from minority backgrounds. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 1951-1960	3.9	9
195	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , <b>2019</b> , 269, 520-529	7.8	127
194	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. <i>Gut</i> , <b>2019</b> , 68, 663-671	19.2	138

193	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 947-954	8.7	23
192	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated?. <i>ANZ Journal of Surgery</i> , <b>2018</b> , 88, 870-875	1	2
191	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e151-e160	21.7	31
190	Chemotherapy in patients with unresected pancreatic cancer in Australia: A population-based study of uptake and survival. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2018</b> , 14, 326-336	1.9	11
189	The PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling. <i>BMC Cancer</i> , <b>2018</b> , 18, 389	4.8	7
188	The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 454	4.8	10
187	A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 70, 135-138	2.3	8
186	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1084-1088	8.7	5
185	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 615-621	3.4	2
184	Association between pancreatic cancer patients' perception of their care coordination and patient-reported and survival outcomes. <i>Palliative and Supportive Care</i> , <b>2018</b> , 16, 534-543	2.5	7
183	Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice. <i>Muscle and Nerve</i> , <b>2018</b> , 57, 650-658	3.4	17
182	Performance status dynamics during treatment with -paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 1389-1396	3.6	3
181	Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3602-3602	2.2	3
180	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e16206-e16206	2.2	4
179	Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 685-700	3.9	95
178	Biliary Stenting in Patients With Pancreatic Cancer: Results From a Population-Based Cohort Study. <i>Pancreas</i> , <b>2018</b> , 47, 80-86	2.6	6
177	Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S31-201, in human sarcoma cell lines. <i>International Journal of Oncology</i> , <b>2018</b> , 52, 2143-2154	4.4	4
176	Anxiety, depression and quality of life in people with pancreatic cancer and their carers. <i>Pancreatology</i> , <b>2017</b> , 17, 321-327	3.8	35



175	Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2017</b> , 13, e291-e297	1.9	2
174	Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. <i>European Journal of Cancer</i> , <b>2017</b> , 73, 22-29	7.5	85
173	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , <b>2017</b> , 54, 74-84	4.8	29
172	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , <b>2017</b> , 128, 1166-1175	4.3	32
171	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 3485-3493	3.9	45
170	Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. <i>Carcinogenesis</i> , <b>2017</b> , 38, 588-591	4.6	15
169	Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals. <i>European Journal of Oncology Nursing</i> , <b>2017</b> , 26, 83-90	2.8	17
168	Information needs of the Chinese community affected by cancer: A systematic review. <i>Psycho-Oncology</i> , <b>2017</b> , 26, 1433-1443	3.9	20
167	Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170814	3.7	121
166	The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172307	3.7	8
165	The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, E10-E15	2.8	2
164	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 951-964	3.5	1
163	New molecular and immunotherapeutic approaches in biliary cancer. <i>ESMO Open</i> , <b>2017</b> , 2, e000152	6	20
162	Communication challenges experienced by migrants with cancer: A comparison of migrant and English-speaking Australian-born cancer patients. <i>Health Expectations</i> , <b>2017</b> , 20, 886-895	3.7	27
161	Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. <i>Pancreas</i> , <b>2017</b> , 46, 203-208	2.6	20
160	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , <b>2017</b> , 17, 262	4.8	12
159	Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 1-7	3.5	13
158	Significance of Phosphorylated Epidermal Growth Factor Receptor and Its Signal Transducers in Human Soft Tissue Sarcoma. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	9

157	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3521-3521	2.2	9
156	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4101-4101	2.2	6
155	Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4109-4109	2.2	4
154	Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4120-4120	2.2	3
153	Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC) An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4136-TPS4136	2.2	8
152	Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 227-227	2.2	1
151	MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. <i>Oncotarget</i> , <b>2017</b> , 8, 9216-9229	3.3	9
150	Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 76722-76737	3.6	37
149	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 134-40	10.3	69
148	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). <i>British Journal of Cancer</i> , <b>2016</b> , 115, 281-9	8.7	48
147	Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. <i>Pancreatology</i> , <b>2016</b> , 16, 1106-1112	3.8	12
146	Using a Delphi process to determine optimal care for patients with pancreatic cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12, 105-14	1.9	7
145	TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 361-7	3.5	14
144	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2728-35	2.2	138
143	A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. <i>Biomacromolecules</i> , <b>2016</b> , 17, 2337-51	6.9	54
142	It's all good on the surface: care coordination experiences of migrant cancer patients in Australia. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 2403-10	3.9	11
141	Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?. <i>European Journal of Cancer</i> , <b>2016</b> , 53, 96-104	7.5	21
140	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 269-80	8.7	66



139	CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 654-60	10.3	62
138	Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. <i>Annals of Oncology</i> , <b>2016</b> , 27, 648-53	10.3	29
137	The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> , <b>2016</b> , 55, 15-26	7.5	33
136	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , <b>2016</b> , 16, 22	4.8	43
135	Key role of pancreatic stellate cells in pancreatic cancer. <i>Cancer Letters</i> , <b>2016</b> , 381, 194-200	9.9	76
134	"I might not have cancer if you didn't mention it": a qualitative study on information needed by culturally diverse cancer survivors. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 409-418	3.9	16
133	Initial survival outcomes for the AGITG GAP study a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4105-4105	2.2	3
132	Outcome of second-line treatment (2L Tx) following nab-paclitaxel (nab-P) + gemcitabine (G) or G alone for metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 333-333	2.2	2
131	Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) a study by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 64-64	2.2	3
130	APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS473-TPS473	2.2	8
129	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. <i>Oncotarget</i> , <b>2016</b> , 7, 21496-509	3.3	18
128	Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines. <i>Anticancer Research</i> , <b>2016</b> , 36, 5765-5771	2.3	19
127	Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 382-382	2.2	
126	Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <i>Medical Journal of Australia</i> , <b>2016</b> , 204, 419-22	4	13
125	Factors associated with quality of care for patients with pancreatic cancer in Australia. <i>Medical Journal of Australia</i> , <b>2016</b> , 205, 459-465	4	16
124	Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 469-78	2.8	38
123	Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 5461-73	4.4	32
122	A tsunami of unmet needs: pancreatic and ampullary cancer patients' supportive care needs and use of community and allied health services. <i>Psycho-Oncology</i> , <b>2016</b> , 25, 150-7	3.9	28

121	Determinants of survival and attempted resection in patients with non-metastatic pancreatic cancer: An Australian population-based study. <i>Pancreatology</i> , <b>2016</b> , 16, 873-81	3.8	10
120	Delineating the Role of IV-Tubulins in Pancreatic Cancer: IV-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. <i>Neoplasia</i> , <b>2016</b> , 18, 753-764	6.4	13
119	Determinants of Outcomes Following Resection for Pancreatic Cancer-a Population-Based Study. <i>Journal of Gastrointestinal Surgery</i> , <b>2016</b> , 20, 1471-81	3.3	18
118	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. <i>European Urology Focus</i> , <b>2016</b> , 2, 341-342	5.1	2
117	The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study. <i>Oncologist</i> , <b>2016</b> , 21, 618-25	5.7	12
116	Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 3589-99	3.9	16
115	Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). <i>European Journal of Cancer</i> , <b>2016</b> , 52, 85-91	7.5	29
114	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1844-53	27.4	538
113	Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 188-94	8.7	52
112	Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1409-1410	27.4	
111	The Potential of panHER Inhibition in Cancer. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 2	5.3	30
110	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , <b>2015</b> , 100, 955-63	6.6	60
109	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 852-60	7.5	21
108	Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 993-1004	3.5	10
107	EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1118-1123	10.3	9
106	Pancreatic cancer: The microenvironment needs attention too!. <i>Pancreatology</i> , <b>2015</b> , 15, S32-8	3.8	59
105	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1571-80	8.7	76
104	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , <b>2015</b> , 17, 391-5	8.1	35

103	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , <b>2015</b> , 15, 564	4.8	125
102	Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables. <i>Oncologist</i> , <b>2015</b> , 20, 523-31	5.7	34
101	Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. <i>British Journal of Surgery</i> , <b>2015</b> , 102, 1459-72	5.3	124
100	Oncology service initiatives and research in regional Australia. <i>Australian Journal of Rural Health</i> , <b>2015</b> , 23, 40-8	1.3	14
99	Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study. <i>Pancreas</i> , <b>2015</b> , 44, 1259-65	2.6	29
98	Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. <i>Frontiers in Nutrition</i> , <b>2015</b> , 2, 10	6.2	14
97	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4276-83	2.2	102
96	Response. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	
95	nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	368
94	Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. <i>Oncologist</i> , <b>2015</b> , 20, 143-50	5.7	99
93	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4003-4003	2.2	8
92	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4115-4115	2.2	4
91	TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9571-9571	2.2	3
90	Antiangiogenic agents (AAs) in metastatic oesophago-gastric cancer (mOGC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15111-e15111	2.2	1
89	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1): A randomized, multidisciplinary, multinational phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4140-TPS4140	2.2	1
88	nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant treatment for resected pancreatic cancer (PC) in a phase III trial (APACT).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4153-TPS4153	2.2	1
87	Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 235-235	2.2	1
86	Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 382-382	2.2	1

85	A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: The AGITG GAP study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 387-387	2.2	4
84	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 9-9	2.2	6
83	βII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 2235-49	3.3	48
82	Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15299-e15299	2.2	
81	Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt347	9.7	191
80	Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 504-12	2.2	254
79	Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis. <i>Quality of Life Research</i> , <b>2014</b> , 23, 2819-30	3.7	5
78	Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 479-80	59.2	40
77	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. <i>Frontiers in Physiology</i> , <b>2014</b> , 5, 2	4.6	45
76	The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. <i>Carcinogenesis</i> , <b>2014</b> , 35, 1891-900	4.6	60
75	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. <i>Frontiers in Physiology</i> , <b>2014</b> , 5, 141	4.6	90
74	Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 996-1001	7.5	33
73	Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1643-9	10.3	76
72	Characterization of fatigue states in medicine and psychiatry by structured interview. <i>Psychosomatic Medicine</i> , <b>2014</b> , 76, 379-88	3.7	17
71	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 10549-10549	2.2	1
70	Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4001-4001	2.2	15
69	Genetic associations of fatigue and other symptom domains after breast cancer treatment: Results from a prospective cohort study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9537-9537	2.2	1
68	APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS4162-TPS4162	2.2	4

67	Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 178-178	2.2	12
66	Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 228-228	2.2	2
65	Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 254-254	2.2	3
64	Circulating biomarkers and outcomes in a single-arm phase II trial of first-line sunitinib alternating with everolimus for advanced renal cell carcinoma (aRCC): EVERSUN ANZUP trial 0901.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 428-428	2.2	1
63	Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4027-4027	2.2	1
62	Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4024-4024	2.2	
61	EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 438-438	2.2	
60	Impact of STAT3 inhibition on survival of osteosarcoma cell lines. <i>Anticancer Research</i> , <b>2014</b> , 34, 6537-452.3		15
59	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1691-703	59.2	3788
58	Clinical and molecular characterization of HER2 amplified-pancreatic cancer. <i>Genome Medicine</i> , <b>2013</b> , 5, 78	14.4	82
57	Chemotherapy-induced peripheral neurotoxicity: a critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2013</b> , 63, 419-37	220.7	410
56	Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4005-4005	2.2	11
55	CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4058-4058	2.2	2
54	Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4059-4059	2.2	3
53	The unmet needs of cancer survivors and their preferences for discussing them with oncologists and general practitioners (GPs).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 9602-9602	2.2	0
52	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA4003-LBA4003	2.2	13
51	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC) A study by the Australasian Gastrointestinal Trials Group (AGITG).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4157-TPS4157	2.2	2
50	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA4003-LBA4003	2.2	55



49	Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA148-LBA148	2.2	34
48	Should culture affect practice? Prognostic discussions with immigrants.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6556-6556	2.2	
47	Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4053-4053	2.2	
46	Targeted therapy in soft tissue sarcoma-a novel direction in therapeutics. <i>Chinese Clinical Oncology</i> , <b>2013</b> , 2, 22	2.3	2
45	STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). <i>International Journal of Oncology</i> , <b>2012</b> , 41, 1181-91	4.4	148
44	A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1335-1340	10.3	41
43	Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3170-9	12.9	95
42	Post-cancer fatigue is not associated with immune activation or altered cytokine production. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2890-2895	10.3	15
41	Reply to A. Giacalone et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4175-4176	2.2	
40	The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. <i>British Journal of Cancer</i> , <b>2012</b> , 106, 61-9	8.7	13
39	Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1805-12	2.2	99
38	Cancer survivorship outcomes in immigrants.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6111-6111	2.2	3
37	Predictors of resilience in women treated for breast cancer: A prospective study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9044-9044	2.2	2
36	Disparities in quality-of-life outcomes in immigrant cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e16507-e16507	2.2	1
35	ATTACHE: A phase III, multicenter, randomized comparison of chemotherapy given prior to and post surgical resection versus chemotherapy given post surgical resection for hepatic metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS3643-TPS3643	2.2	
34	Usefulness of medical oncologists' estimates of survival time in people with advanced cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 9087-9087	2.2	
33	PAN1: A randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS4137-TPS4137	2.2	
32	Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 519-25	3.5	9



31	Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. <i>Oncologist</i> , <b>2011</b> , 16, 708-16	5.7	148
30	If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1333-44	5.7	75
29	A serious complication of selected internal radiation therapy: case report and literature review. <i>Oncologist</i> , <b>2010</b> , 15, 830-5	5.7	47
28	Role of pancreatic stellate cells in pancreatic cancer metastasis. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 2585-96	5.8	257
27	Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4089-95	2.2	128
26	Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1243-9	2.2	125
25	The successful management of two pregnancies with wild type metastatic gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2009</b> , 5, 187-192	1.9	1
24	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 998-1004	8.7	73
23	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , <b>2009</b> , 132, 2712-23	11.2	155
22	ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, LBA4505-LBA4505	2.2	10
21	GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4616-4616	2.2	2
20	Pancreatic stellate cells: partners in crime with pancreatic cancer cells. <i>Cancer Research</i> , <b>2008</b> , 68, 2085-93	10.1	351
19	Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2008</b> , 4, 170-174	1.9	2
18	Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy. <i>Clinical Colorectal Cancer</i> , <b>2007</b> , 6, 578-82	3.8	2
17	Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , <b>2007</b> , 97, 464-71	8.7	29
16	Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. <i>BMC Cancer</i> , <b>2006</b> , 6, 240	4.8	69
15	Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6, 297-304	3.8	27
14	Hypersensitivity reactions to oxaliplatin: Can patients be rechallenged?. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2006</b> , 2, 175-179	1.9	2

13	Phase II study of vinflunine in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 429-34	4.3	17
12	Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study. <i>Oncology</i> , <b>2005</b> , 69, 326-32	3.6	24
11	Oxaliplatin-induced neurotoxicity and the development of neuropathy. <i>Muscle and Nerve</i> , <b>2005</b> , 32, 51-60	4.4	170
10	Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2005</b> , 92, 832-7	8.7	21
9	Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5795-804	2.2	239
8	Modern management of pancreatic carcinoma. <i>Internal Medicine Journal</i> , <b>2004</b> , 34, 475-81	1.6	28
7	Fatigue and psychological distress--exploring the relationship in women treated for breast cancer. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 1689-95	7.5	52
6	Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. <i>Pancreas</i> , <b>2004</b> , 29, 179-87	2.6	440
5	Communicating in a multicultural society. II: Greek community attitudes towards cancer in Australia. <i>Internal Medicine Journal</i> , <b>2002</b> , 32, 289-96	1.6	50
4	Administration of imiquimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 178, 858-61	7	57
3	What is hemoglobin A1c? An analysis of glycosylated hemoglobins by electrospray ionization mass spectrometry. <i>Clinical Chemistry</i> , <b>1998</b> , 44, 1951-1958	5.5	144
2	Australian Leukaemia Study Group myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma. <i>British Journal of Haematology</i> , <b>1997</b> , 97, 38-45	4.5	26
1	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. <i>Quality of Life Research</i> ,	3.7	0